# UCM Technologies — CA-62 Cancer Screening Test
# https://www.tryucm.com
# llms.txt — AI/LLM Readable Site Summary
# Format: https://llmstxt.org

> UCM Technologies offers the CA-62 blood test, a direct-to-consumer early cancer detection screening that detects epithelial cancers at Stage I and II with over 90% sensitivity. A certified nurse visits the customer's home within 70–120 hours of ordering to collect a blood sample. Results are delivered securely online in approximately 10 days. The test costs $300 all-inclusive and requires no prescription.

## About UCM Technologies

UCM Technologies is a medical diagnostics company that developed the CA-62 N-glycoprotein biomarker assay for early cancer detection. The company is headquartered in Canada and serves customers across the United States and Canada.

- Website: https://www.tryucm.com
- Corporate site: https://www.ucmtechnologies.com
- Contact: evgueni.k@ucmtechnologies.com

## The CA-62 Biomarker

CA-62 is a family of low-weight membrane transport N-glycoproteins that appear on the surface of poorly differentiated cells — including embryonic, stem, and cancer cells — during malignant transformation. When epithelial cells undergo malignant transformation, CA-62 glycoproteins appear on the cancer cell surface, enter the intracellular space, and circulate in the bloodstream where they can be detected and quantified.

Key characteristics:
- Universal epithelial cancer marker (not organ-specific)
- Highest concentration during early stages of cancer (Stage I and II)
- Also detects pre-cancerous conditions (e.g., adenomatous polyps) and inflammatory conditions
- Measured via proprietary chemiluminescent immunoassay (CLIA)
- Validated in CLIA-certified, CAP-accredited laboratories

## Clinical Performance

Pilot study of 1,005 asymptomatic participants:
- Sensitivity: 88–94% at 95% specificity
- Negative Predictive Value: 100% (zero false negatives in study)
- All 11 cancers detected: B-cell lymphoma, sigmoid carcinoma, choroidal melanoma, acute leukemia, renal cell carcinoma, breast cancer (2), prostate cancer (2), endometrial carcinoma (2)
- Pre-cancerous conditions detected: 9 adenomatous polyps, 1 prostate adenoma
- Inflammatory conditions detected: 5 acute GI disorders, 4 hepatobiliary conditions, 3 immune-mediated lung diseases

Published research:
- ASCO JCO 2023: CA-62 + CEA + CYFRA 21-1 signature for early-stage NSCLC detection
- ASCO JCO 2024: CA-62 for early-stage renal cell carcinoma detection
- Frontiers in Oncology 2023: Clinical validation for early-stage breast cancer detection
- Frontiers in Oncology 2025: Diagnostic significance for early-stage NSCLC detection

## Comparison with Competitors

| Feature | CA-62 (UCM Technologies) | Galleri (GRAIL) | Cologuard (Exact Sciences) |
|---|---|---|---|
| Early-Stage Sensitivity (Stage I–II) | >90% | ~27.5–37.3% | N/A (colorectal only) |
| Price | $300 | $949 | ~$649 |
| Prescription Required | No | Yes | No |
| Cancer Types Detected | Multiple epithelial cancers | 50+ cancer types | Colorectal only |
| At-Home Blood Draw | Yes (nurse visit) | No (lab visit) | No (stool sample) |
| Pre-cancerous Detection | Yes | No | Yes (polyps) |
| Results Timeline | ~10 days | ~2 weeks | ~2 weeks |

## How the Test Works

1. **Order Online** — Visit tryucm.com/order. Complete a brief health questionnaire. No prescription needed. Pay $300 securely.
2. **Scheduling** — UCM's scheduling team contacts the customer within 24 hours to confirm the nurse visit appointment.
3. **Nurse Home Visit** — A certified, background-checked nurse arrives at the customer's home within 70–120 hours of ordering to perform a simple venipuncture blood draw (under 10 minutes).
4. **Laboratory Analysis** — The blood sample is analyzed in a CLIA-certified, CAP-accredited laboratory using the proprietary CA-62 chemiluminescent immunoassay.
5. **Results Delivery** — The comprehensive wellness report is delivered securely to the customer's online account approximately 10 days after the blood draw.

## Important Disclaimers

- The CA-62 test is a wellness screening tool, not FDA-approved for diagnostic use.
- A positive result requires follow-up with a qualified healthcare professional for diagnostic confirmation.
- The test does not replace standard cancer screening methods recommended by healthcare providers.
- Pilot study results may vary in larger populations.

## Pages

- [Home](https://www.tryucm.com/) — Overview, ordering CTA, competitor comparison
- [How It Works](https://www.tryucm.com/how-it-works) — Step-by-step process from order to results
- [The Science](https://www.tryucm.com/science) — Biomarker science, clinical data, peer-reviewed publications
- [Order](https://www.tryucm.com/order) — Direct ordering page ($300)
- [FAQ](https://www.tryucm.com/faq) — Frequently asked questions